Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with AZD9150 or AZD5069 in advanced solid tumors and recurrent/metastatic head and neck squamous cell carcinoma
2015-002525-19Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, danvatirsen and azd5069 in advanced nonhematological malignancy and head and neck squamous cell carcinoma (HNSCC) (6 arms), sponsored by AstraZeneca. Started Sep 2015; status: completed.
02
Drugs
durvalumabdanvatirsenazd5069
03
Conditions
advanced nonhematological malignancyhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2015-002525-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002525-19.